William Blair Analysts Lower Earnings Estimates for APLS

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Equities researchers at William Blair reduced their Q4 2026 EPS estimates for shares of Apellis Pharmaceuticals in a research note issued on Tuesday, July 1st. William Blair analyst L. Hanbury-Brown now forecasts that the company will post earnings of $0.00 per share for the quarter, down from their previous forecast of $0.04. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last issued its earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The company had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same quarter in the previous year, the company posted ($0.54) EPS. The company’s quarterly revenue was down 3.2% on a year-over-year basis.

A number of other equities analysts also recently commented on APLS. Mizuho cut their price objective on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a “neutral” rating for the company in a research report on Wednesday, May 14th. Citigroup lowered their price target on shares of Apellis Pharmaceuticals from $49.00 to $41.00 and set a “buy” rating on the stock in a research note on Thursday, May 22nd. Bank of America cut shares of Apellis Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the stock from $41.00 to $23.00 in a research note on Friday, May 9th. Scotiabank lowered their price objective on shares of Apellis Pharmaceuticals from $28.00 to $20.00 and set a “sector perform” rating on the stock in a research note on Thursday, May 8th. Finally, Cantor Fitzgerald initiated coverage on shares of Apellis Pharmaceuticals in a research note on Tuesday, April 29th. They issued an “overweight” rating and a $44.00 price objective on the stock. Nine analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Apellis Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $39.79.

Apellis Pharmaceuticals Stock Up 0.9%

APLS stock opened at $17.99 on Thursday. The company has a fifty day moving average price of $18.15 and a 200 day moving average price of $23.59. Apellis Pharmaceuticals has a 12 month low of $16.10 and a 12 month high of $42.47. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -10.05 and a beta of 0.67. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the stock. Avoro Capital Advisors LLC raised its stake in Apellis Pharmaceuticals by 10.0% during the fourth quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company’s stock worth $390,011,000 after acquiring an additional 1,111,111 shares in the last quarter. Vanguard Group Inc. grew its holdings in shares of Apellis Pharmaceuticals by 0.8% during the first quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company’s stock worth $221,551,000 after purchasing an additional 84,331 shares during the last quarter. AQR Capital Management LLC grew its holdings in shares of Apellis Pharmaceuticals by 119.6% during the first quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company’s stock worth $89,173,000 after purchasing an additional 2,220,977 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Apellis Pharmaceuticals by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company’s stock worth $58,699,000 after purchasing an additional 28,426 shares during the last quarter. Finally, Deutsche Bank AG grew its holdings in shares of Apellis Pharmaceuticals by 1.8% during the fourth quarter. Deutsche Bank AG now owns 1,778,377 shares of the company’s stock worth $56,748,000 after purchasing an additional 30,867 shares during the last quarter. 96.29% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Apellis Pharmaceuticals

In related news, General Counsel David O. Watson sold 5,000 shares of the company’s stock in a transaction on Monday, June 16th. The stock was sold at an average price of $18.77, for a total value of $93,850.00. Following the completion of the transaction, the general counsel directly owned 133,730 shares in the company, valued at approximately $2,510,112.10. This represents a 3.60% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 6.50% of the stock is currently owned by company insiders.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).